By Brian Mahoney ( August 12, 2013, 4:31 PM EDT) -- AstraZeneca PLC on Monday asked the Federal Circuit to block four generic-drug makers from launching no-name versions of its Pulmicort Respules pediatric asthma medication, saying a lower court relied too heavily on expert testimony in finding one of its patents as obvious and anticipated....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.